Crossmark

Identifying prevalence and inpatient outcomes of anemia and hidradenitis suppurativa

Published Online: 2022-12-21

Authors

Patel, Shrey

Patel, Shiv

Shah, Sareena

Lio, Peter A.
License Information

Text and Data Mining valid from 2022-12-21

Version of Record valid from 2022-12-21
More Information

Article History

Received: 18 September 2022

Revised: 6 December 2022

Accepted: 12 December 2022

First Online: 21 December 2022

Declarations

:

: SP, SP, and SS report no conflicts of interest. PAL reports research grants/funding from the National Eczema Association, AOBiome, Regeneron/Sanofi Genzyme, and AbbVie; is on the speaker’s bureau for Regeneron/Sanofi Genzyme, Pfizer, Incyte, Eli Lilly, LEO, Galderma, and L'Oreal; reports consulting/advisory boards for Almirall, ASLAN Pharmaceuticals, Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO Pharmaceuticals, AbbVie, Eli Lilly, Micreos, L'Oreal, Pierre-Fabre, Johnson & Johnson, Level Ex, KPAway, Unilever, Menlo Therapeutics, Theraplex, IntraDerm, Exeltis, AOBiome, Realm Therapeutics, Altus Labs, Galderma, Verrica, Amyris, Bodewell, Burt's Bees, My-Or Diagnostics, and Kimberly-Clark. In addition, Dr. Lio has a patent pending for a Theraplex product with royalties paid and is a Board member and Scientific Advisory Committee Member of the National Eczema Association.

: IRB approval was not required as the study uses a publicly available data source with de-identified information.

Document is current